NATIONAL INSTITUTE OF NUTRITION

INDIAN COUNCIL OF MEDICAL RESEARCH
JAMAI-OSMANIA P.O., HYDERABAD 500007.
Ph: 040-27197322, 413,313 Fax.No.040-27003317/27000556
Website: www.ninindia.org Email: ninstores@yahoo.com

TENDER NOTICE

No.ST/1/ADVT/PCT/B.Din/2017-18 **Date: 16.08.2017**

Sealed offers are invited up to 5:00 p.m. on 18.9.2017 in two bid system (technical & financial) from reputed suppliers/authorized dealers/manufacturing companies of Indian/Foreign origin, for the supply of

1. **Recombinant Plasmid DNA expressing HIV immunogens for Preclinical Toxicity Studies;**

2. **Recombinant Modified Vaccinia Ankara (rMVA) viruses Expressing HIV immunogens for Preclinical Toxicity studies.**

The tender documents can be downloaded from the website: www.ninindia.org, http://eprocure.gov.in along with the Questionnaire and Guide lines. Quotations will be accepted till **5.00 p.m on 18.9.2017** The technical bids **will be opened on 21.9.2017 at 10-30 A.M. onwards** in the presence of the Bidders. The date of Price bid opening will be intimated to the **qualified bidders** only at a later date.

The Director-in charge, NIN reserves the right to accept or reject any or all the offers without assigning any reason/s thereof.

Sd/
Admn. Officer (Stores)

NATIONAL INSTITUTE OF NUTRITION

INDIAN COUNCIL OF MEDICAL RESEARCH
JAMAI-OSMANIA P.O., HYDERABAD 500007.
Ph: 040-27197322, 413,313 Fax.No.040-27003317/27000556
Website: www.ninindia.org Email: ninstores@yahoo.com

TENDER NOTICE

No.ST/1/ADVT/PCT/B.Din/2017-18 **Date: 16.8.2017**

Sealed offers are invited up to 5:00 p.m. on 18.09.2017 in two bid system (technical & financial) from reputed suppliers/authorized dealers/manufacturing companies of Indian/Foreign origin, for the supply of

1. **Recombinant plasmid DNA expressing HIV immunogens for Precllinical Toxicity Studies**

2. **Recombinant Modified Vaccinia Ankara (rMVA) viruses Expressing HIV immunogens for Preclinical Toxicity studies**

The tender documents can be downloaded from the website: www.ninindia.org, http://eprocure.gov.in along with the Questionnaire and Guide lines. Quotations will be accepted till **5.00 p.m on 18.9.2017** The technical bids **will be opened on 21.9.2017 at 10-30 A.M. onwards** in the presence of the Bidders. The date of Price bid opening will be intimated to the **qualified bidders** only at a later date.

Brief Description of Tender : Sl. No. 1

Requirements for manufacture of FIVE different Recombinant plasmids expressing HIV immunogens and ONE Vector of 270 mg each, for use in Preclinical toxicity studies:

1. The company should have a GLP facility which is at least three years old with appropriate regulatory approvals for commercial manufacture and supply of Recombinant plasmid DNA.
2. The Plasmid DNA should be supplied along with the certificate of analysis containing the following information:

   a. Plasmid DNA should be predominantly (80% and above) in super coiled form.
   b. The Endotoxin levels should not exceed 40EU/mg plasmids
   c. Plasmid DNA should not contain >1% bacterial host macro molecules (DNA, RNA, protein).
   d. The Plasmid DNA should be dissolved in sterile buffer (0.9% NaCl).
   e. The total requirement of plasmid DNA is 1.6 g (Lyophilized powder) of which FIVE different constructs and ONE vector, each plasmid DNA should be supplied 270 mg with different concentrations in vials (Refer Annexure - 1).
   f. The restriction map of the recombinant plasmids with appropriate restriction digestion pattern to be provided.
   g. The presence of each of the 'Gene of Interest' in rDNA construct should be validated by 'nucleotide sequencing'.
   h. A single formulation containing 'five gene of interest' of rDNA constructs should be prepared along with vector alone (Plasmid Vector) as placebo construct.

Brief Description of Tender : Sl. No. 2

Requirements for manufacture of FIVE different rMVA viruses expressing HIV immunogens and Vector with each of, 259 X 10^8 pfu of each virus, for use in Preclinical Toxicity studies:

1. The company should have a GLP facility which is at least three years old with appropriate regulatory approvals for commercial manufacture and supply of rMVA viruses.
2. The rMVA viruses should be supplied along with the Certificate of analysis containing the following information:
   a. Propagation on production of rMVA viruses should be done in Specific Pathogen free (SPF) chick embryo fibroblast.
   b. The total requirement of Modified Vaccinia Ankara (MVA) viruses is 155 x 10^9 pfu of which FIVE different constructs and ONE vector, each should be supplied 259 x 10^8 pfu in vials with different Concentrations (pfu/ml) in sterile saline (0.9%NaCl) (Refer Annexure - 2).
   c. The final product should be free from avian retro virus as demonstrated by metagenomics.
   d. The final product should be free from host RNA, DNA and Protein.
   e. The final product should be free from avian pathogens listed in Indian Pharmacopeia 2014, vol.1 item no: 2.7.7, pages 292-294.
   f. The presence of each of the 'Gene of Interest' in rMVA virus should be validated by PCR using appropriate primers followed by DNA sequencing.
   g. A single formulation containing 'five gene of interest' rMVA constructs should be prepared along with vector alone (MVA) as placebo construct.

3. The following approvals may be submitted for Participation in Tender Process

3.1. Mandatory:

a. The company should have IBSC committee to undertake the rDNA and rMVA constructs preparation

Or

In case of International Agency, similar type of approval from respective regulatory body, have to be provided.

3.2. Optional:

b. The 'DSIR Certification'.
c. cGMP manufacturing approval from CDSCO and DCGI.

Or

International agencies have to provide similar type of approvals from respective regulatory bodies.

Terms & Conditions:

Offers should be submitted in a separate cover containing (Technical bid cover, Price Bid cover & EMD cover, Tender Fee Cover) with tender reference number, document number, due date super-scribed on the envelope, duly enclosing a Demand Draft of **Rs.1,000/-** each **(Rupees One thousand only)**, drawn in favour of **DIRECTOR, NATIONAL INSTITUTE OF NUTRITION, HYDERABAD** towards tender fee**.** Cheque and Postal Orders will not be accepted. Offers received without the tender fee will be rejected.

Bidders have to enclose the Questionnaire duly filled and signed along with the Technical Bid. Offers without the filled in Questionnaire/unsigned questionnaire will be summarily rejected.

Quotations will be accepted till **5.00 p.m on 18.9.2017.** The technical bids **will be opened on 21.9.2017 at 10-30 A.M. onwards** in the presence of the Bidders. The date of Price bid opening will be intimated to the **qualified bidders** only at a later date.

EMD equivalent to 3% (three percent only) of the cost (rounded of to nearest thousand) should be submitted in the form of a **Demand Draft drawn** in favour of the **DIRECTOR, NATIONAL INSTITUTE OF NUTRITION,** payable at Hyderabad along with the price bid in a **SEPARATE COVER**. A copy of the DD towards EMD **"blocking the amount"** may be submitted along with the Technical Bid.

Successful Bidders have to submit 10% value of the Order as Performance guarantee **(compulsory)** in the form of Bank guarantee, which will be retained till the completion of the experiment on successful basis. **"Offers received without EMD/incomplete/ without questionnaire/unsigned questionnaire, without tender document fee and received after the due date will be summarily rejected"**. The **Director, NIN,** reserves the right to accept **or** reject any or all the offers without assigning reason/s thereof**.**

sd/-Admn. Officer (Stores)
for Director